JS107

JS107 is a recombinant humanized antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a tumor-associated antigen highly expressed in certain cancers such as gastric and pancreatic cancer. The drug consists of an anti-Claudin 18.2 monoclonal antibody linked to the cytotoxic payload monomethyl auristatin E (MMAE). Upon binding to CLDN18.2 on tumor cells, JS107 is internalized and releases MMAE inside the cell, disrupting microtubule function and inducing cell death through tubulin inhibition. Additionally, the ADC retains immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), enhancing its antitumor activity via both direct cytotoxic effects and immune-mediated mechanisms[1][5]. Preclinical studies have shown significant antitumor efficacy with good safety profiles in animal models[5].

Other names

anti-Claudin 18.2 antibody-drug conjugate JS107anti-Claudin18.2 antibody-drug conjugate JS107anti-Claudin-18.2 antibody-drug conjugate JS107